Nanorods of vanadium compounds: synthesis, characterisation, and application in electrochemical energy storage

The synthesis and characterisation of nanorods of vanadium pentoxide, V(2)O(5), vanadium trioxide, V(2)O(3), vanadium dioxide, VO(2)(B), and vanadium nitride, VN, are presented, and their application in electrochemical supercapacitors and lithium-ion batteries is outlined. Specifically, a novel method for the preparation of V(2)O(5) nanorods is discussed. It involves ball milling as a first step and controlled annealing as a second step. Nanorods of V(2)O(5) can be converted into those of other vanadium-related phases by simple chemical reduction treatments. Such chemical transformations are pseudomorphic and often topotactic, that is, the resulting nanorods belong to a different chemical phase but tend to retain the original morphology and preferential crystal orientation dictated by parent V(2)O(5) crystals.

The corresponding properties of nanorods for their prospective application in electrochemical energy storage (lithium-ion batteries and electrochemical supercapacitors) are discussed. The synthesised V(2)O(5) nanorods possess a stable cyclic behaviour when they are used in a cathode of a lithium-ion battery and are suitable for use in an anode. VN nanorods synthesised by NH(3) reduction of V(2)O(5) were found to possess pseudocapacitive properties in aqueous electrolytes.

Effect of flame-retarding additives on surface chemistry in Li-ion batteries

This study examined the properties of 1 wt.% vinylene carbonate, vinyl ethylene carbonate, and diphenyloctyl phosphate additive electrolytes as a promising way of beneficially improving the surface and cell resistance of Li-ion batteries. The additive electrolytes were dominant both in surface formation and internal resistance. In particular, electrochemical impedance spectroscopy, Fourier transform infrared spectroscopy and scanning electron microscopy confirmed that diphenyloctyl phosphate is an excellent additive to the electrolyte in the Li-ion batteries due to the improved co-intercalation of the solvent molecules.

Using lithium as a neuroprotective agent in patients with cancer

Neurocognitive impairment is being increasingly recognized as an important issue in patients with cancer who develop cognitive difficulties either as part of direct or indirect involvement of the nervous system or as a consequence of either chemotherapy-related or radiotherapy-related complications. Brain radiotherapy in particular can lead to significant cognitive defects. Neurocognitive decline adversely affects quality of life, meaningful employment, and even simple daily activities. Neuroprotection may be a viable and realistic goal in preventing neurocognitive sequelae in these patients, especially in the setting of cranial irradiation. Lithium is an agent that has been in use for psychiatric disorders for decades, but recently there has been emerging evidence that it can have a neuroprotective effect.

This review discusses neurocognitive impairment in patients with cancer and the potential for investigating the use of lithium as a neuroprotectant in such patients.

The science and practice of lithium therapy

Introduction: Despite more that 60 years of clinical experience, the effective use of lithium for the treatment of mood disorder, in particular bipolarity, is in danger of becoming obsolete. In part, this is because of exaggerated fears surrounding lithium toxicity, acute and long-term tolerability and the encumbrance of life-long plasma monitoring. Recent research has once again positioned lithium centre stage and amplified the importance of understanding its science and how this translates to clinical practice.

Objective: The aim of this paper is to provide a sound knowledge base as regards the science and practice of lithium therapy.

Method: A comprehensive literature search using electronic databases was conducted along with a detailed review of articles known to the authors pertaining to the use of lithium. Studies were limited to English publications and those dealing with the management of psychiatric disorders in humans. The literature was synthesized and organized according to relevance to clinical practice and understanding.

Results: Lithium has simple pharmacokinetics that require regular dosing and monitoring. Its mechanisms of action are complex and its effects are multi-faceted, extending beyond mood stability to neuroprotective and anti-suicidal properties. Its use in bipolar disorder is under-appreciated, particularly as it has the best evidence for prophylaxis, qualifying it perhaps as the only true mood stabilizer currently available. In practice, its risks and tolerability are exaggerated and can be readily minimized with knowledge of its clinical profile and judicious application.

Conclusion: Lithium is a safe and effective agent that should, whenever indicated, be used first-line for the treatment of bipolar disorder. A better understanding of its science alongside strategic management of its plasma levels will ensure both wider utility and improved outcomes.

Gram-scale and template-free synthesis of ultralong tin disulfide nanobelts and their lithium ion storage performances

Ultralong SnS2 nanobelts with a high production yield up to _98% were synthesized via a gram-scale and template-free solvothermal route. The synthetic mechanism of these intriguing ultralong nanobelts was proposed to be from the synergetic effect of the layered CdI2-type structure of SnS2 and surfacemodification of the capping reagent dodecanethiol. The resulting SnS2 nanobelts showed a high specific capacity of 640 mA h g_1 and stable cycling ability (560 mA h g_1 after 50 cycles), which is much better than a graphite anode.